Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 1
1999 2
2000 7
2001 7
2002 7
2003 10
2004 4
2005 7
2006 4
2007 9
2008 9
2009 12
2010 6
2011 7
2012 8
2013 11
2014 15
2015 14
2016 7
2017 9
2018 9
2019 6
2020 6
2021 9
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for id: 50848

171 results

Results by year

Filters applied: . Clear all
Page 1
Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa.
Communal L, Medrano M, Sircoulomb F, Paterson J, Köbel M, Rahimi K, Hoskins P, Tu D, Lheureux S, Oza A, Ailles L, Provencher D, Rottapel R, Mes-Masson AM. Communal L, et al. Mod Pathol. 2020 Nov;33(11):2361-2377. doi: 10.1038/s41379-020-0586-0. Epub 2020 Jun 8. Mod Pathol. 2020. PMID: 32514162 Free article.
Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways.
Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G. Orlandella FM, et al. Mol Carcinog. 2019 Jul;58(7):1181-1193. doi: 10.1002/mc.23001. Epub 2019 Mar 4. Mol Carcinog. 2019. PMID: 30834573
Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM. Leech AO, et al. Breast Cancer Res. 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1. Breast Cancer Res. 2018. PMID: 30458861 Free PMC article.
JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.
Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desantis V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A. Solimando AG, et al. Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287. Epub 2017 Sep 28. Leukemia. 2018. PMID: 29064484 Free PMC article.
171 results